Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v15-EN Version v5-EN
Language English English
Date Updated 2023-01-16 2022-07-07
Drug Identification Number 02264307 02264307
Brand name HEPARIN SODIUM INJECTION, USP HEPARIN SODIUM INJECTION, USP
Common or Proper name Heparin Sodium Injection, USP 10 000 USP units/mL MD Vial 1 mL Heparin Sodium Injection, USP 10 000 USP units/mL MD Vial 1 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients HEPARIN SODIUM HEPARIN SODIUM
Strength(s) 10000UNIT 10000UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS
Packaging size 1mL 1mL
ATC code B01AB B01AB
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2022-02-01 2022-02-01
Estimated end date 2023-02-21 2022-08-31
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments On backorder effective September 1, 2022 until February 21, 2023 The product will be placed on allocation once available. Contract customers will be allocated 100% of their historical monthly demand, effective February 1, 2022.
Health Canada comments